These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37282505)

  • 21. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
    Kirchhof P; Pecen L; Bakhai A; de Asmundis C; de Groot JR; Deharo JC; Kelly P; Levy P; Lopez-de-Sa E; Monteiro P; Steffel J; Waltenberger J; Weiss TW; Laeis P; Manu MC; Souza J; De Caterina R
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):47-57. PubMed ID: 35881467
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The duration of anticoagulation bridging therapy in clinical practice may significantly exceed that observed in clinical trials.
    Deerhake JP; Merz JC; Cooper JV; Eagle KA; Fay WP
    J Thromb Thrombolysis; 2007 Apr; 23(2):107-13. PubMed ID: 17221327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulation in patients with atrial fibrillation and active cancer: an international survey on patient management.
    Boriani G; Lee G; Parrini I; Lopez-Fernandez T; Lyon AR; Suter T; Van der Meer P; Cardinale D; Lancellotti P; Zamorano JL; Bax JJ; Asteggiano R;
    Eur J Prev Cardiol; 2021 May; 28(6):611-621. PubMed ID: 33624005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A comparison of CAS risk model and CHA
    Deng JL; He L; Jiang C; Lai YW; Long DY; Sang CH; Jia CQ; Feng L; Li X; Ning M; Hu R; Dong JZ; Du X; Tang RB; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Sep; 50(9):888-894. PubMed ID: 36096706
    [No Abstract]   [Full Text] [Related]  

  • 26. The HAS-BLED score predicts bleedings during bridging of chronic oral anticoagulation. Results from the national multicentre BNK Online bRiDging REgistRy (BORDER).
    Omran H; Bauersachs R; Rübenacker S; Goss F; Hammerstingl C
    Thromb Haemost; 2012 Jul; 108(1):65-73. PubMed ID: 22534746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study.
    Blann AD; Banerjee A; Lane DA; Torp-Pedersen C; Lip GY
    Int J Cardiol; 2015 Dec; 201():693-8. PubMed ID: 26379097
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial.
    Hohnloser SH; Camm AJ; Cappato R; Diener HC; Heidbüchel H; Mont L; Morillo CA; Lanz HJ; Rauer H; Reimitz PE; Smolnik R; Kautzner J
    Europace; 2021 Jan; 23(1):65-72. PubMed ID: 33249467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: the AFCAS study.
    Kiviniemi T; Airaksinen KE; Rubboli A; Biancari F; Valencia J; Lip GY; Karjalainen PP; Weber M; Laine M; Kirchhof P; Schlitt A;
    Int J Cardiol; 2015 Mar; 183():105-10. PubMed ID: 25662060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Introduction of Non-Vitamin K Antagonist Anticoagulants Strongly Increased the Rate of Anticoagulation in Hospitalized Geriatric Patients with Atrial Fibrillation.
    Djukic M; Braun LM; Unkel S; Jacobshagen C; Nau R
    Drugs Aging; 2018 Sep; 35(9):859-869. PubMed ID: 30066299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initiation of oral anticoagulation after acute ischaemic stroke or transient ischaemic attack: timing and complications of overlapping heparin or conventional treatment.
    Audebert HJ; Schenk B; Tietz V; Schenkel J; Heuschmann PU
    Cerebrovasc Dis; 2008; 26(2):171-7. PubMed ID: 18628615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease.
    Qamar A; Antman EM; Ruff CT; Nordio F; Murphy SA; Grip LT; Greenberger NJ; Yin OQP; Choi Y; Lanz HJ; Mercuri MF; Braunwald E; Giugliano RP
    J Am Coll Cardiol; 2019 Jul; 74(2):179-189. PubMed ID: 31296289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
    Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
    JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48.
    Giugliano RP; Ruff CT; Rost NS; Silverman S; Wiviott SD; Lowe C; Deenadayalu N; Murphy SA; Grip LT; Betcher JM; Duggal A; Dave J; Shi M; Mercuri M; Antman EM; Braunwald E;
    Stroke; 2014 Aug; 45(8):2372-8. PubMed ID: 24947287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
    Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
    Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selecting the right anticoagulant for stroke prevention in atrial fibrillation.
    Kundnani NR; Rosca CI; Sharma A; Tudor A; Rosca MS; Nisulescu DD; Branea HS; Mocanu V; Crisan DC; Buzas DR; Morariu S; Lighezan DF
    Eur Rev Med Pharmacol Sci; 2021 Jul; 25(13):4499-4505. PubMed ID: 34286492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study.
    Nielsen PB; Søgaard M; Jensen M; Ording AG; Lip GY
    Int J Stroke; 2022 Jun; 17(5):536-544. PubMed ID: 34142600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.
    Goette A; Merino JL; Ezekowitz MD; Zamoryakhin D; Melino M; Jin J; Mercuri MF; Grosso MA; Fernandez V; Al-Saady N; Pelekh N; Merkely B; Zenin S; Kushnir M; Spinar J; Batushkin V; de Groot JR; Lip GY;
    Lancet; 2016 Oct; 388(10055):1995-2003. PubMed ID: 27590218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
    Akashi S; Oguri M; Ikeno E; Manita M; Taura J; Watanabe S; Hayashi T; Akao M; Okumura K; Akishita M; Yamashita T
    JAMA Netw Open; 2022 Aug; 5(8):e2228500. PubMed ID: 35997978
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation.
    Fox KAA; Virdone S; Pieper KS; Bassand JP; Camm AJ; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Oto A; Misselwitz F; Piccini JP; Dalgaard F; Turpie AGG; Verheugt FWA; Kakkar AK;
    Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):214-227. PubMed ID: 33892489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.